Changeflow GovPing Pharma & Drug Safety Modulation of Wnt signalling in ocular disorders
Routine Notice Added Final

Modulation of Wnt signalling in ocular disorders

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent application EP3924381A1 for Surrozen Operating, Inc., covering Wnt signaling modulators and their use in treating ocular disorders. The patent application includes claims on therapeutic compositions and methods for eye diseases. This IP filing affects companies developing treatments for ophthalmic conditions involving Wnt pathway modulation.

What changed

The European Patent Office published patent application EP3924381A1 titled 'Modulation of Wnt signalling in ocular disorders' filed by Surrozen Operating, Inc. The application covers methods and compositions for modulating Wnt signaling to treat eye diseases, including claims on therapeutic proteins and antibodies targeting Wnt pathway components.

For pharmaceutical and biotech companies active in ophthalmology drug development, this patent establishes intellectual property protection that may restrict freedom to operate in the Wnt-based ocular therapeutics space. Companies should conduct freedom-to-operate analyses and consider potential licensing discussions with Surrozen.

What to do next

  1. Assess freedom to operate for Wnt pathway ocular disease programs
  2. Review patent claims for potential licensing opportunities
  3. Monitor for related patent filings in ophthalmology space

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

MODULATION OF WNT SIGNALLING IN OCULAR DISORDERS

Publication EP3924381A1 Kind: A1 Apr 01, 2026

Applicants

Surrozen Operating, Inc.

Inventors

LI, Yang, TU, Shengjiang, LEE, Sungjin, YEH, Wen-Chen

IPC Classifications

C07K 16/18 20060101AFI20230622BHEP C07K 16/28 20060101ALI20230622BHEP A61P 27/02 20060101ALI20230622BHEP C12N 15/11 20060101ALI20230622BHEP A61K 38/17 20060101ALI20230622BHEP C07K 14/435 20060101ALI20230622BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3924381A1

Who this affects

Applies to
Pharmaceutical companies Medical device makers
Industry sector
3254 Pharmaceutical Manufacturing 3345 Medical Device Manufacturing
Activity scope
Patent grant IP licensing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.